Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) has earned a respected four-star ranking.

With that in mind, let's take a closer look at BioMarin's business, and see what CAPS investors are saying about the stock right now.

BioMarin facts

Headquarters (founded)

Novato, Calif. (1996)

Market Cap

$1.41 billion

Industry

Biotechnology

TTM Revenue

$310.1 million

Management

CEO Jean-Jacques Bienaime (since 2005)
CFO Jeffrey Cooper (since 2005)

Compound Annual Revenue Growth (over last five years)

91.3%

Competitors

Biogen Idec (NASDAQ:BIIB)
Genzyme (NASDAQ:GENZ)

CAPS members bullish on BMRN also bullish on

Johnson & Johnson (NYSE:JNJ)
Google (NASDAQ:GOOG)

CAPS members bearish on BMRN also bearish on

Citigroup (NYSE:C)
First Solar (NASDAQ:FSLR)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, 878 of the 918 members who have rated BioMarin -- some 96% -- believe the stock will outperform the S&P 500 going forward. These bulls include bigbubba49 and All-Star TSIF, who is ranked in the top 1% of our community.

Last year, bigbubba49 highlighted BioMarin's focus on orphan drug development:

Biomarin targets diseases caused by genetic defects. Most of these are relatively rare, so there is not a large market, and this makes it less likely that a lot of competitors will get into the business. … Although this does not create a wide moat, it does create somewhat of a sustainable competitive advantage, as the research infrastructure and personal contacts developed for one genetic disorder will apply to a fair extent to other disorders.

In a pitch from three weeks ago, TSIF elaborates on BioMarin as a bankable biotech bet:

Their announcement that earnings were flat on expenses sent the stock downward recently. Their pipeline of new drugs was dramatically weakened when Riquent was pulled from Phase III trial based on results. Overall, however, BioMarin appears to me to be a strong drug company. I rate them by their both strong revenue AND having drugs in the pipeline to add to their growth. With margins above 10%, strong yoy growth, and cash on hand exceeding debt, I believe BioMarin has good potential based on its current valuations.

What do you think about BioMarin, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. BioMarin and Google are Motley Fool Rule Breakers recommendations. Biogen is a Stock Advisor selection. Johnson & Johnson is a choice of Income Investor. The Fool's disclosure policy always gets a perfect score.